Biotechnology

Within its first three years on the market, SPINRAZA approached a critical milestone. By the end of 2020, an anticipated 10,000 patients ranging from newborns to adults world-wide would use SPINRAZA to treat their SMA (spinal muscular atrophy).

Biogen wanted to host a 3-day internal meeting for regional heads, members of the Global ELT and affiliates. Special guests including HCPs, Patient Advocacy Groups and patients were invited to participate in select portions of the meeting near the Boston HQ.

Unfortunately, the March 2020 meeting was impacted by the Pandemic lockdown just a few days shy of load-in. Elements meant for the main stage and breakouts were converted into a Comms rollout in April and May.

The Strength of 10,000

Theme

Patient Story Room Drop Card